Abstract 2144: Mutations in ERBB4 may account for clinical resistance of melanomas to inhibitors of the RAS/RAF/MEK/MAPK pathway
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs18-2144
Abstract: Introduction: Despite advancements made in the treatment of metastatic melanoma, the 5-year survival rate remains about 20%. The high mortality rate is thought to be due to there being no other clinically actionable targets other… read more here.
Keywords: ras raf; mek mapk; mapk pathway; melanoma ... See more keywords